Resilience and Mayo Clinic create biomanufacturing partnership for rare and complex conditions

By Rachel Arthur

- Last updated on GMT


Related tags biomanufacturing Us

Biomanufacturing company National Resilience has announced a strategic collaboration with Mayo Clinic in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions.

The partnership will focus on therapies derived from biologics — cells, blood, enzymes, tissues, genes, or genetically engineered cells — for use in medicines. It will help Mayo Clinic and third-party biotechs to advance cell therapies into clinical trials.

The partners say the collaboration will help establish Rochester, Minnesota, as a center of excellence for biomanufacturing cell and regenerative technologies.

From biomanufacturing to business support

Resilience was founded in 2020 with a pledge to broaden access to complex medicines through innovations in technology-focused biomanufacturing. It is building a network of high-tech, end-to-end manufacturing solutions so that treatments can be made quickly, safely, and at scale.

In the new partnership, Resilience will collaborate with Mayo’s Center for Regenerative Medicine in Two Discovery Square, located within the research corridor of the Destination Medical Center economic development initiative in Rochester.

Resilience and Mayo will build embedded process and analytical development labs, as well as quality control labs. This “embedded” approach allows for closer proximity and collaboration to jointly develop and progress cell therapies and other advanced modalities into clinical care, say the partners.

The collaboration also aims to attract third-party biotech companies interested in sponsoring clinical trials for new therapeutics, as well as collaborating on their process and analytical development. It also wants to advance biologic discoveries towards early stage clinical trials.

The collaboration focuses on the following initiatives:

  • Process and analytical development
  • Biomanufacturing for early-stage cell & gene therapeutics
  • Analytical testing and quality control required for manufacturing commercial-grade biopharmaceuticals
  • A business incubator where healthcare entrepreneurs, startups, and industry experts can work together on forwarding breakthrough technologies to market
  • Access to clinical trial capabilities and patients

“By combining our organizations’ capabilities in biomanufacturing and medical innovation, we have an opportunity to deliver complex and innovative therapeutics to patients in need,”​ said Rahul Singhvi, ScD, Chief Executive Officer of Resilience.

“We are delighted to continue to grow our presence across North America, as our collaboration with Mayo Clinic will establish Rochester as a center of excellence for biomanufacturing cell and regenerative technologies.”

The collaboration will also allow Mayo to leverage Resilience’s network: Resilience currently has 11 facilities across North America totaling more than 1 million square feet of manufacturing space. With capacity and capabilities set to continue to grow this year (Resilience has projects underway at several existing sites across modalities), the company says its network is agile enough to scale customer projects from process and analytical development through preclinical, clinical, and to large scale commercial manufacturing.

Last year, Resilience launched a five-year alliance with Harvard University​, focusing on the development and manufacturing of complex medicines including biologics, vaccines, nucleic acids and cell and gene therapies. 

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more